Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.

Christopher VinnardShruthi RavimohanNeo TamuhlaVijay D IvaturiJotam PasipanodyaShashikant SrivastavaChawangwa ModongoNicola M ZetolaDrew WeissmanTawanda GumboGregory P Bisson

Published in: British journal of clinical pharmacology (2016)

HIV/TB patients with high levels of immune activation demonstrated impaired isoniazid clearance. Future efforts should determine the role of this relationship in clinical hepatotoxicity events.

Keyphrases

human immunodeficiency virus
mycobacterium tuberculosis
antiretroviral therapy
hepatitis c virus
hiv infected
hiv aids
hiv positive
pulmonary tuberculosis
current status
hiv testing
quality improvement
emergency department
adverse drug